Uncategorized

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023

Verona Pharma plc, announces an oral presentation on an additional analysis from its successful Phase 3 ENHANCE-1 study with ensifentrine for the treatment of chronic obstructive pulmonary disease will be presented at the European Respiratory Society International Congress 2023.

Verona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023 Read More »

FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition

Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s Biologics License Application for crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, for the treatment of paroxysmal nocturnal hemoglobinuria.

FDA Accepts Application for Genentech’s Crovalimab for the Treatment of PNH, a Rare Life-Threatening Blood Condition Read More »

Scroll to Top